Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 02 2016 - 4:05PM
Business Wire
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical
company focused on delivering innovative therapies to patients with
kidney disease through the biology of hypoxia-inducible factor
(HIF), today announced the company granted a newly hired executive
an option to purchase 130,000 shares of the company’s common stock
with a per share exercise price of $8.61, the closing price on the
grant date. These options will vest as to 25% of the total number
of shares subject to the option on the first anniversary of the
grant date. The remaining 75% of shares will vest ratably on the
first day of each calendar quarter over the next three years. The
stock options were inducements material to the new employee
entering into employment with the company, and issued in reliance
on NASDAQ Listing Rule 5635(c)(4).
About Akebia TherapeuticsAkebia Therapeutics, Inc. is a
biopharmaceutical company headquartered in Cambridge,
Massachusetts, focused on delivering innovative therapies to
patients with kidney disease through hypoxia-inducible factor
biology. Akebia’s lead product candidate, vadadustat, is an oral
therapy in development for the treatment of anemia related to
chronic kidney disease in both non-dialysis and dialysis patients.
Akebia has commenced its vadadustat Phase 3 Program, which includes
the PRO2TECT studies for non-dialysis patients with anemia
secondary to chronic kidney disease and the INNO2VATE studies for
dialysis-dependent patients. For more information, please visit our
website at www.akebia.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161202005531/en/
Akebia ContactAJ Gosselin, 617-844-6130Manager, Corporate
Communicationsagosselin@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2023 to Apr 2024